Skip to content
Medical Health Aged Care, Research Development


La Trobe University 2 mins read
Research leaders Dr Quynh Nhu Dinh and Dr Michael De Silva

For immediate release
31 January 2024

Scientists from La Trobe University and the Hudson Institute have demonstrated that cells from placentas could have therapeutic benefits for patients suffering from high blood pressure.

The research, led by La Trobe Senior Lecturer in Physiology and Pharmacology, Dr Michael De Silva, and published in Scientific Reports, has advanced La Trobe’s recent studies into using placenta cells for stroke recovery, has passed human safety trials.

In the next phase, this new therapy will be assessed for its efficacy at reducing disability caused by stroke, pending Therapeutic Goods Administration approval.

“Here we have built on the groundbreaking results of La Trobe’s previous studies using these cells in stroke models,” Dr De Silva said. “If infused within a day after a stroke, the cells target the affected area of the brain, and reduce inflammation and nerve cell death."

“We realised that we could test if similar protection could be seen in reducing the damage high blood pressure causes in the body and we found that the treatment reduced inflammation in blood vessels," Dr De Silva said.

High blood pressure, also known as hypertension, is the leading cause of strokes and heart attacks, and over time creates inflammation in the arteries and can lead to vascular dementia. More than one in every three Australians over the age of 18 has high blood pressure.

The research team at La Trobe led by Dr Michael De Silva, Dr Quynh Nhu Dinh, and Professor Chris Sobey found that the cells, collected by the Hudson Institute from placentas donated by mothers after caesareans, reduced inflammation and prevented cognitive impairment.

"Blood pressure control rates are at an alarmingly low level of 32 per cent in Australia. While a drug can reduce high blood pressure, these cells could target inflammation in the arteries caused by hypertension and therefore reduce the associated risks of cardiovascular disease and cognitive impairment," Dr De Silva said.

Dr De Silva said while the research was in its early stages and the team would continue to work on how this knowledge may benefit patients with high blood pressure, he was satisfied to see that this research could eventually lead to a new form of therapy that reduced damage to blood vessels and the brain when blood pressure was high.

For further interviews, contact Sue Smethurst:, 0418 643 520


More from this category

  • Medical Health Aged Care
  • 24/07/2024
  • 02:10
CGFNS International

CGFNS International Joins WHO Stakeholder Network to Advance Rehabilitation Care

PHILADELPHIA, PA / ACCESSWIRE / July 23, 2024 / CGFNS International, a worldwide leader in international credentials evaluation and certification to support health worker careers, has been inducted into the World Rehabilitation Alliance (WRA).CGFNS International The WRA is the World Health Organization's global network of stakeholders whose mission is to advocate for the implementation of WHO's Rehabilitation 2030 initiative, which aims to improve rehabilitation management and investment, build a high-quality rehabilitation workforce and services, and enhance data collection on rehabilitation."We are delighted to receive this recognition of our extensive work in developing practical solutions to improve rehabilitation care for the…

  • Medical Health Aged Care
  • 23/07/2024
  • 23:56

Eurofins Environment Testing Australia Wins the National Association of Testing Authorities (NATA) Excellence Award for Their Microplastics Laboratory

SYDNEY–BUSINESS WIRE– Eurofins Environment Testing Australia (EETA) was honoured to receive the National Association of Testing Authorities (NATA) Excellence Award during NATA’s “Accreditation Matters”…

  • Contains:
  • Medical Health Aged Care
  • 23/07/2024
  • 22:11
KBI Biopharma, Inc.

Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization challenges DURHAM, N.C.–BUSINESS WIRE– KBI Biopharma, Inc. (KBI),…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.